PTO/SB/64 (10-05) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	PETITION FOR REVIVAL OF AN APP ABANDONED UNINTENTIONALLY U		Docket Number (Optional) PC25293A	
	First named inventor: Michael J. Munchhof			
	Application No.: 10/667,183	Art Unit: 1625		
	Filed: 09/17/2003	Examiner: Morris	, Patricia L.	
	Title: NOVEL TRIAZOLE COMPOUNDS AS TRANSFOR	RMING GROWTH FACTORS (TGF) INHIBITOR	₹ऽ	
01/10/2006	BESHAH2 00000094 161445 10667183			
01 FC:1453	Attention: Office of Petitions Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 FAX (571) 273-8300			
	NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (571) 272-3282.			
	The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus an extensions of time actually obtained.			
	APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION			
	NOTE: A grantable petition requires the following items: (1) Petition fee; (2) Reply and/or issue fee; (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995; and for all design applications; and (4) Statement that the entire delay was unintentional.			
	1.Petition fee Small entity-fee \$ (37 CFR 1		status. See 37 CFR 1.27.	
	✓ Other than small entity – fee \$ 1,500.00 (37 CFR 1.17(m))			
τ.	Reply and/or fee A. The reply and/or fee to the above-noted Office action in the form of(identify type of reply):			
	has been filed previously of is enclosed herewith.	n		
	B. The issue fee and publication fee has been paid previously o	e (if applicable) of \$ <u>1.700.00</u> . n	<i>,</i>	

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection	PTO/SB/64 (10-05) Approved for use through 07/31/2006. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number.			
Terminal disclaimer with disclaimer fee	of information unless it displays a valid OWD condornatibe.			
Since this utility/plant application was filed on or after June 8, 19	995, no terminal disclaimer is required.			
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for other than a small entity) disclaiming the required period of ti PTO/SB/63).				
4. STATEMENT: The entire delay in filing the required reply from the dufiling of a grantable petition under 37 CFR 1.137(b) was unintentional Trademark Office may require additional information if there is a questional abandonment or the delay in filing a petition under 37 CFR 1.137(b) subsections (III)(C) and (D)).]	I. [NOTE: The United States Patent and stion as to whether either the			
WARNING:				
Petitioner/applicant is cautioned to avoid submitting personal information in contribute to identity theft. Personal information such as social security numbers (other than a check or credit card authorization form PTO-2038 submittee USPTO to support a petition or an application. If this type of personal information to the USPTO. Petitioners/applicants should consider redacting such personal information to the USPTO. Petitioner/applicant is advised that the record of a patent application (unless a non-publication request in compliance with 37 CFR of a patent. Furthermore, the record from an abandoned application may also referenced in a published application or an issued patent (see 37 CFR 1.14). Of the application file and the applicat	umbers, bank account numbers, or credit card litted for payment purposes) is never required by mation is included in documents submitted to the ation from the documents before submitting them ication is available to the public after publication 1.213(a) is made in the application) or issuance so be available to the public if the application is Checks and credit card authorization forms PTO-d therefore are not publicly available.			
(1) Theholus / Suc	an 5, 2006			
Signature	Date			
Nicholas J. Sisti	54,453			
Typed or printed name	Registration Number, if applicable			
Pfizer Inc., Eastern Point Road, MS 8260-1611	860-686-2883			
Address	Telephone Number			
Groton, CT 06340				
Address				
Enclosures: 🗸 Fee Payment				
Reply				
Terminal Disclaimer Form				
Additional sheets containing statements establishing	g unintentional delay			
Other: Fee Address Indication Form				
CERTIFICATE OF MAILING OR TRANSMISS	SION [37 CFR 1 8/a)]			
I hereby certify that this correspondence is being: Deposited with the United States Postal Service on the depostage as first class mail in an envelope addressed to: Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Transmitted by facsimile on the date shown below to the Office as (571) 273-8300. 01/05/2006 Date	late shown below with sufficient Mail Stop Petition, Commissioner for			

PC25293A

PC2529A

PC2529

IN RE APPLICATION OF:

Munchhof, Michael, J., et al.

Examiner: P. Morris

APPLICATION NO.: 10/667,183

Group Art Unit: 1625

FILING DATE: September 17, 2003

Confirmation No. 8579

TITLE: Novel Triazole Compounds as Transforming :

Growth Factor (TGF) Inhibitors

Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

STATEMENT UNDER 37 CFR § 1.137(b)

With regards to the failure to timely pay the issue and publication fee for the above referenced case, applicants assert that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to 37 CFR § 1.137(b) was unintentional. Applicants also enclose the petition fee under 37 CFR § 1.17(m) and required issue and publication fees.

The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Deposit Account No. 16-1445. Two (2) copies of this sheet are enclosed herewith.

Respectfully submitted,

Date: \m S

Nicholas J. Sisti, Ph.D., J.D.

Corporate Counsel Reg. No. 54,453

Pfizer Inc Patent Department Eastern Point Road, MS8260-1611 Groton, Connecticut 06340 (860) 686-2883